Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.60 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8884369 | 0.98 | SIGMAR1 (0.61) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8883356 | 0.86 | SIGMAR1 (0.62) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10924871 | 0.86 | HDAC3 (0.50) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4319038 | 0.85 | MAPT (0.64) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8996654 | 0.85 | MAPT (0.64) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18530341 | 0.85 | MAPT (0.64) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1817688 | 0.84 | RAB9A (0.64) | MAPTALDH1A1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL10647146 | 0.84 | MAPT (0.47) | SIGMAR1MAPTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5211495 | 0.84 | PDK1 (0.55) | MAPTALDH1A1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL2557430 | 0.84 | CFD (0.55) | MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-5696110-A | ANTIULCER AGENTS | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-09 | — | — | US | claimed |
| EP-0652871-A1 | BENZODIAZEPINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-05-17 | — | — | EP | claimed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023119320-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-29 | — | — | WO | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
| US-10842798-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3265456-B1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-5696110-A | ANTIULCER AGENTS | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-09 | — | — | US | disclosed |
| EP-0652871-A1 | BENZODIAZEPINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-05-17 | — | — | EP | disclosed |
| US-4752621-A | Arylalkyl amines useful for lowering intraocular pressure | SYNTEX (U.S.A.) INC. (US) | 1988-06-21 | — | — | US | disclosed |
| US-4642378-A | Arylalkyl amines useful for lowering intraocular pressure | SYNTEX (U.S.A.) INC. (US) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | SIGMAR1 647/4885MAPT 2243/4885GRIN2D 4717/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | SIGMAR1 125/4885MAPT 680/4885GRIN2D 304/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SIGMAR1 659/4885MAPT 1799/4885GRIN2D 393/4885 |
| US-10842798-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SIGMAR1 659/4885MAPT 1799/4885GRIN2D 393/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | SIGMAR1 659/4885MAPT 1799/4885GRIN2D 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.